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D
ementia refers to a syndrome that is characterised by progressive deterioration of cognitive
functions. Neuropsychiatric symptoms, such as apathy, agitation, and depression, are also
common. With increasing loss of function, a patient is gradually robbed of his or her
independence. Eventually, placement in a nursing home may be necessary. Patients with
dementia usually survive 7—10 years after onset of symptoms. Dementia places a tremendous
burden not only on caregivers, but also on society, and has already been established as one of the
major challenges of this century.1
Epidemiology refers to the medical science that studies frequencies of disease.2 Measures of
frequency that are often used in epidemiology are prevalence and incidence. The concept of
prevalence refers to the number of patients with a disease at a certain moment in time, whereas
measures of incidence reflect the number of new cases over time. Although important for health
care planners, the knowledge of frequency of disease in itself is not the goal of epidemiology.
Rather, the aim is to gain insight into the mechanisms that cause disease, eventually to be able to
cure or prevent disease. Therefore, frequencies are studied in relation to determinants, or risk
factors. Although marked as ‘‘the epidemic of our century’’, still surprisingly little is known about
the epidemiology of dementia. In this chapter, a brief overview will be given of the epidemiology
and risk factors of dementia. Furthermore, we comment on some specific methodological
problems associated with studies in dementia.
SYNDROME AND DISEASEc
The syndrome of dementia may be caused by various underlying diseases, each characterised by a
specific constellation of signs and symptoms in combination with a presumed underlying
substrate of neuropathology (fig 1). Alzheimer’s disease (AD) is the most prevalent cause of
dementia. It is a neurodegenerative disorder, generally assumed to be caused by neuritic plaques
and neurofibrillary tangles accumulating in the brain. The second most prevalent cause of
dementia is vascular dementia (VaD), which may be caused by various types of vascular
pathology in the brain, such as ‘‘large vessel’’ (large territorial or strategical infarctions) and
‘‘small vessel’’ (lacunes and white matter hyperintensities) disease. Other frequent causes of
dementia include frontotemporal lobar degeneration and dementia with Lewy bodies. It is often
difficult (if not impossible) to reliably distinguish between subtypes of dementia (we will come
back to this subject in the section on methodological issues). Therefore, epidemiological studies
often focus on dementia as a whole, sometimes giving separate numbers for the two most
important subtypes—AD and VaD.
PREVALENCE
Prevalence is defined as the proportion of a population that has disease at a specific point in time.
Prevalence estimates vary highly between studies. These variations may be due to variations in
study population—that is, reflect real differences. For example, age is the most important risk
factor for dementia. Differences in age between populations will result in different estimates of
prevalence. Alternatively, and just as plausible, is the assumption that differences in prevalence
estimates are caused by methodological differences, such as study design and diagnostic
procedure. One solution to obtain more certainty about the value of prevalence is to combine data
from multiple studies in a meta-analysis. Meta-analyses have two advantages. First, small
differences due to methodological differences between studies level out. Secondly, and more
importantly, the analysis is based on a far larger sample than a single study could ever realise,
resulting in more precise estimates.
Pooled estimates of prevalence
In 2000, prevalence data from 11 European population based studies were pooled to obtain stable
estimates of prevalence of dementia in the elderly (. 65 years).3 Age standardised prevalence was
6.4% for dementia (all causes), 4.4% for AD, and 1.6% for VaD. Prevalence of dementia was higher
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in women than in men and nearly doubled with every five
year increase in age: 0.8% in the group age 65–69 years and
28.5% at age 90 years and older (fig 2). Of all dementia cases,
54% suffered AD. Prevalence of AD showed the steepest
increase with age, from 0.6% in the group age 65–69 years to
22.2% in the group aged 90 years and older. VaD accounted
for 16% of cases, and prevalence increased with age from
0.3% (65–69 years) to 5.2% (90+ years). More recently,
prevalence rates for dementia were compared among 12
population based European studies. Crude prevalence rates
varied between 5.9% (Italy, the Counselice study) and 9.4%
(the Netherlands, Rotterdam study).1 Again, an almost
exponential increase with age and a female excess—mostly
after age 75—was described.
Dementia with young onset
Most studies on prevalence of dementia focus on subjects
aged over 65 years. Although age is well established as its
most important risk factor, dementia may also affect people
under the age of 65. Few data exist on the prevalence of
dementia in younger people. A recent study in the UK was
designed to determine the prevalence of dementia in people
under the age of 65 in a large catchment area (total
population of 567 500 people) and use these figures to
estimate the number of younger people affected by dementia
in the UK.4 The prevalence of dementia in those aged 30–64
was 54 per 100 000. For those aged 45–64, the prevalence was
98 per 100 000. Like the studies mentioned above describing
prevalence over the age of 65, there was a strong age
dependency: from the age of 35 years onwards, the
prevalence of dementia approximately doubled with every
five year increase in age. In contrast with studies describing
populations over 65, males seem at a higher risk to become
demented before they reach the age of 65 than females.
Extrapolating these figures nationally suggests that there
are well over 18 000 people with dementia under the age of
65 in the UK. At 34%, AD was also the most prevalent cause
of dementia among younger people, although with less
prominence than at old age (fig 3). The relative prevalence of
VaD (18%) roughly equals the prevalence at old age.
Frontotemporal dementia (12%) and alcohol related demen-
tia (10%) were relatively more prevalent among the younger
population than among elderly populations. These figures
underline the fact that, although relatively uncommon,
dementia does develop in younger subjects, and it should
always be part of the differential diagnosis in patients with
cognitive complaints. Furthermore, these data also highlight
the differences between dementia in younger people and
dementia in older people, with frontotemporal dementia and
alcohol related dementia being relatively common causes of
dementia in the younger age group.
‘‘When I’m sixty four’’
Nearly 40 years ago, The Beatles launched a famous song
which included the words ‘‘Will you still need me, will you
still feed me when I’m 64’’. At that time Paul McCartney,
looking at his 64 year old father, wondered how life would be
at 64—considered ‘‘old’’ at that time apparently—probably
also being afraid for age related diseases, such as dementia.
In the coming decades, the financial and emotional burden
placed by dementia on the working age population will rise
notably. As the age distribution of the western population
shifts, the rapid increase of the prevalence of dementia with
increasing age means that both the number of affected
individuals and the affected proportion of the total popula-
tion are increasing. This will be especially prominent in
Europe, where the median age of the population is higher
than in all other parts of the world. Based on several meta-
analyses of epidemiological studies and the population
projections of the United Nations, the number of prevalent
cases in Europe in the year 2000 was about seven million.5
Within the next 50 years, this number is estimated to more
Figure 1 Causes of dementia with late onset (> 65 years). AD,
Alzheimer’s disease; VaD, vascular dementia. Based on Lobo et al.3
Figure 2 Pooled prevalence of dementia by sex. Based on Lobo et al.3
Figure 3 Causes of dementia with young onset (, 65 years). Based
on Harvey et al.4
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than double to well over 16 million patients with dementia.
Not only will the number of patients with dementia increase;
in the same time span, the working age population will
considerably decrease in number (fig 4). While in the year
2000, there was a ratio of 69 working age persons to one
demented person, this ratio will decrease to 21:1 in 2050.
In this paragraph, an overview of the prevalence of
dementia has been given. Prevalence is determined by both
the number of new cases over a given period of time, and by
the duration of survival once patients have the disease.2
Death results in a decrease of prevalence; therefore, diseases
that quickly lead to death may have low prevalence, even if
they occur frequently, while diseases with long survival have
higher prevalence, even if they occur with lower frequency.
From the above it follows that studies based on prevalent
cases yield associations that reflect the determinants of
survival with disease just as much as the causes of disease.
This can result in misleading situations—for example, if a
new treatment would positively influence the course of
dementia by lengthening survival (although not curing the
disease), this would result in a higher prevalence. In such a
situation, the paradoxical situation may occur that this
medication would be positively associated with the preva-
lence of dementia, and so be misconstrued as a causative
agent. For this reason incidence, rather than prevalence, is
the desired measure of disease frequency.
INCIDENCE
Incidence refers to the number of new cases over a given
period of time. The observed number of new cases depends
on the evaluated duration of follow up. To be able to compare
studies with varying duration of follow up, incidences per
year are usually given. Furthermore, within a given study,
length of follow up time may differ between subjects. To
profit from all the available information, the length of time at
risk is determined for every person. The total length of follow
up time is obtained after summing all person-times, and
represented as the number of person-years of follow up. Most
studies on incidence report incidence rates that are calculated
as the number of new cases divided by the person-years at
risk. Incidence rates are usually represented as number of
new cases per 1000 person-years.
Pooled estimates of incidence
In the same collaborative effort that pooled prevalence data
of European studies, data on incidence of dementia of eight
population based European studies were compared and
pooled.6 In total, there were 42 996 person-years of follow
up with 835 new dementia cases. Of these, 60–70% were
diagnosed with AD and 15–20% with VaD. Incidence rates of
dementia increased exponentially with age from 2.4 per 1000
person-years in the 65–69 age group, to 70.2 per 1000 person-
years in the 90+ age group. Rates among women were higher,
especially above the age of 80 (fig 5). The rates continued to
increase with age in women, whereas the increase reached a
plateau in men at age 85. For AD, findings were comparable,
with pooled incidence rates increasing from 1.2 per 1000
person-years among 65–69 year olds to 53.5 among subjects
over 90 years old.
Will we be all demented at the age of 140?
The question of whether the incidence rates reach a plateau
at a certain age is important, as an exponential increase in
Figure 4 Working age population and
number of working age persons per one
demented person( = ratio) in Europe
using age and sex adjusted mean
numbers of prevalent cases. Based on
Wancata et al.5
Figure 5 Pooled incidence rates of dementia by sex. Based on
Fratiglioni et al.6
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incident AD would suggest that the disease is an inevitable
consequence of aging, whereas convergence to a fixed value
or a decline could suggest that an element of the population
has reduced vulnerability, owing perhaps to genetic or
environmental factors.7 Results with respect to incidence
increasing with age have been conflicting, with some studies
suggesting an ongoing increase with advancing age, whereas
other studies suggest that incidence rates reach a plateau
after a certain age. This issue is difficult to resolve, however,
as the oldest age groups are always underrepresented,
resulting in less precise estimations. The Cache County in
Utah, USA, is known for the longevity of its inhabitants. The
relatively large proportion of extremely old individuals
provides the opportunity to give reliable estimates of incident
dementia among the oldest old. There were 185 new cases of
dementia (123 AD) among 3308 participants who contrib-
uted 10 541 person-years of follow up.7 The incidence of
dementia increased with advancing age from 2 per 1000
person-years in the group aged ( 68, to peak with 122 per
1000 person-years in the 90–92 age group, and decline in the
93+ age group (110 per 1000 person-years). The incidence of
dementia was higher in females over the age of 80. If
incidence rates would indeed plateau at a certain age, then
the future public health burden of dementia and AD, albeit
still enormous, might be less than previously projected.
Variation across regions?
Incidence rates have been found to vary between studies.
Methodological issues partly account for these differences,
but it is also conceivable that the variable estimates reflect
real geographical differences. There are substantial differ-
ences in possible risk factors for dementia between regions.
Such chronic disease risk factor variation is thought to be
responsible for the wide variation seen in other diseases of
older age such as cancer and cardiovascular disease (for
example, differences between North and South Europe).
Given the available evidence for risk factors of dementia and
the pronounced variation in vascular risk factors across
regions, there could be parallel variation in the incidence of
dementia. In fact, the pooled analysis of eight European
studies mentioned above suggests a geographical dissocia-
tion, with higher incidence rates being found among the
oldest old of northwestern countries than among southern
countries.6 To assess variation in incidence within country,
the Medical Research Council cognitive function and ageing
study (MRC CFAS) compared incidence rates among five
sites with different risk patterns and mortality rates.8 As
reported before, incidence was observed to rise with age,
particularly above the age of 75, and continued to increase for
both males and females into the oldest age groups. However,
there was no convincing evidence for variation across sites,
and incidence rates did not reflect the variations in the
prevalence of possible risk factors in these sites.
RISK FACTORS
The estimates of frequency of dementia are important by
themselves, as they underline the extent of the health care
problem as created by dementia. Although important for
health care planners, the frequency of disease in itself is not
the most important issue. Rather, we need to gain insight
into the mechanisms that cause dementia, to be able to
develop therapeutic agents that can slow down or even cure
these diseases. Risk factors are studied to find out the basic
mechanisms leading to dementia. By influencing these risk
factors we hope to be able to modify the course of the disease.
Studies on risk factors for dementia have mainly focused
on AD, as it is the most frequent cause of dementia. Age is
the most well known risk factor for dementia. Studies of
prevalence and incidence of dementia and AD have consis-
tently shown an almost exponential increase with advancing
age, in that estimates of both prevalence and incidence
double with every five year increase in age. In addition,
female sex has repeatedly been shown to be associated with
an increased risk of AD, especially at old age.6 7 Other risk
factors for AD include genetic and vascular factors.
Genetic risk factors
Only a small proportion of all individuals with dementia
suffers from a familial form of dementia, caused by an
autosomal dominant mutation. Mutations in several genes
(including Ab precursor protein, presenilin 1, and presenilin
2) have been shown to cause AD, but these genetic forms of
AD account for less than 5% of all cases. The largest
proportion of AD cases is therefore ‘‘sporadic’’. However,
genetic factors also seem to influence non-familial cases of
AD. The ‘‘common disease/common variant’’ hypothesis
postulates that common disorders, such as AD, are also
governed by common DNA variants.9 These variants sig-
nificantly increase disease risk but are neither necessary nor
sufficient to actually cause a specific disorder. Rather, these
risk genes display intricate patterns of interaction with each
other as well as with non-genetic variables, modifying the
risk for a disease. To date, only one such factor has been
identified in AD. The apoliprotein E gene presents in three
allelic forms (e2, e3, and e4), of which the e4 allele is a risk
factor for AD.10 APOE e4 itself is neither necessary nor
sufficient to cause AD, but instead operates as a genetic risk
modifier. The well known effect of age on AD is modified by
APOE, as age of onset is lower in APOE e4 positives.7 In
addition, it has been suggested that APOE interacts with
vascular risk factors.
Vascular risk factors
There is abundant evidence that vascular factors play a role in
AD. Vascular risk factors such as hypertension, diabetes
mellitus, smoking, and heart disease all have been shown to
be associated with AD.11 Explanations for these associations
include: (1) the coincidence of common disorders in the
elderly; (2) vascular and cerebrovascular disease precipitating
AD; (3) an additive or synergistic (AD + vascular) pathogen-
esis of dementia; and (4) misclassification of vascular
dementia as AD.11 12 At this moment, the question about
the primary and secondary pathology in AD is unlikely to be
answered. The mechanisms linking vascular risk factors to
AD remain unclear. Atherosclerosis has been postulated as
one common mechanism mediating the association between
AD and various vascular risk factors. However, statistical
models have failed to demonstrate an important mediating
role for atherosclerosis as one common factor. Either the
measures of extracranial atherosclerosis are not suitable as
proxies for intracranial atherosclerosis, or there are other
mechanisms whereby cardiovascular risk factors are asso-
ciated with AD.
METHODOLOGICAL ISSUES
A brief overview has been given of the current knowledge of
prevalence, incidence, and risk factors of dementia. Although
v5
NEUROLOGY IN PRACTICE
www.jnnp.com
progress in understanding dementia is being made, the basic
mechanisms causing the majority of dementias are still not
known, and satisfying therapeutic options are as yet not
available. Studies of dementia are hampered by certain
methodological issues inherent to the disorder. These
methodological issues may influence the results of studies
and be partly responsible for variability in results across
studies. Without intending to give a complete overview of the
methodological issues associated with the study of dementia,
we would like to address briefly four important issues here.
Diagnostic procedure
The most important problem with respect to studying
dementia and AD is defining the outcome. As yet, there is
no single diagnostic test for AD or most of the other types of
dementia. The diagnosis of AD is based on clinical criteria,
and can be graded as possible, probable, or definite. Several
sets of criteria are available, of which the criteria of the
National Institute of Neurological and Communicative
Disorders and Stroke (NINCDS) and the Alzheimer’s
Disease and Related Disorders Association (ADRDA), dating
from 1984, are the most commonly used.13 The diagnostic
work-up of dementia is time and cost intensive. In large
population based studies, it is impossible to assess every
subject with a complete diagnostic work-up. Using medical
records to identify cases would lead to an underestimation of
the number of individuals with dementia, as many of the
cases of dementia are never diagnosed in a formal setting.
Therefore, large population based studies usually employ a
stepwise approach to identify cases. Most studies use one of
two possible stepwise approaches. (1) All subjects are
assessed using a screening test. Only those performing below
a certain cut off level receive an extensive assessment. A
drawback of this approach is the low sensitivity of screening
tests. Subjects who are demented but score above cut-off on
the screening test are missed. These may include mild cases,
and individuals with good cognitive reserve due to, for
example, high educational level. (2) A subsample, stratified
by certain characteristics such as age, sex, and performance
on a screening test, receives an extensive diagnostic assess-
ment. Results are extrapolated to the entire sample. Inherent
to this approach is the fact that not all cases will receive an
extensive assessment, which may result in lack of precision.
The use of different criteria to diagnose dementia, and the
variable approaches to operationalise these criteria in large
samples, can result in highly varying estimates of frequency.
The difficulty of diagnosing mild dementia can lead to an
additional problem in incidence studies, as cases that are very
mild and therefore not recognised at baseline may be wrongly
counted as incident cases at follow up, resulting in biased
estimates.14
Insidious onset
A second—and related—methodological problem inherent to
dementia is the insidious onset of the disorder.
Neuropathological changes, eventually leading to the clinical
syndrome of dementia, may start as early as decades before
the disease becomes clinically overt. In analogy with the
gradually accumulating neuropathology, the transition from
healthy to demented is also gradual, rather than abrupt. The
moment when dementia is diagnosed is in fact arbitrary.
Moreover, the artificial dichotomisation between healthy and
demented does not do justice to the continuum of cognitive
(dys)function. The concept of mild cognitive impairment
(MCI) has been developed to account for the transitional
phase between healthy and demented.15 However, introdu-
cing concepts like MCI only shifts the problem, as the borders
between healthy and MCI and between MCI and demented
remain just as arbitrary and unclear. A possible solution
would be to discard the arbitrary distinction between normal
and demented, and instead use a continuous outcome, such
as a test of cognitive function. This would have several
advantages. First, costs and time can be saved as the
extensive diagnostic work-up is not necessary anymore.
Second, by abolishing the artificial dichotomisation into
normal and demented, the continuum of cognitive decline is
done more justice. This approach also provides the opportu-
nity to study progression of decline within demented indivi-
duals.
Biomarkers
A third issue reflects the complex relationship between the
syndrome of dementia and the underlying diseases. When we
talk of AD, we refer to the syndrome that is characterised by
progressive memory problems, which usually has an insi-
dious onset, etc. However, at the moment the diagnosis of AD
is made, we assume to know the underlying neuropatholo-
gical substrate—that is, neuritic plaques and neurofibrillary
tangles. We assume to know this, because during lifetime, it is
impossible to directly measure neuropathology. In fact, post-
mortem studies have shown that this assumption in many
cases is wrong.16 In a report of the MRC CFAS of the first 209
subjects (48% demented) who came to necropsy, Alzheimer-
type pathology and vascular pathology were equally common,
and both correlated with cognitive decline. Most subjects had
mixed pathology. Approximately one third of clinically
demented patients did not fulfil neuropathological criteria
for definite AD, whereas an equally large proportion of non-
demented elderly subjects did fulfil these criteria.16
Neuropathologically, the distinction between different types
of dementia, and even between demented and non-demen-
ted, seems to be very difficult. The question arises that if it is
useful to make clinical distinctions between subtypes of
dementia, neuropathology may not even exist. A step towards
directly measuring disease, rather than clinical phenotype,
would be to take biomarkers as outcome of studies. Both
neuroimaging and cerebrospinal fluid can provide useful
surrogate markers that give a more direct impression of the
pathology. In this way, the possibility of different types of
pathology coexisting within one subject is appreciated. For
example, magnetic resonance imaging (MRI) measures
suggestive of Alzheimer-type pathology and vascular pathol-
ogy can be evaluated simultaneously.
Cross sectional versus longitudinal studies
Studies with a longitudinal design are preferred over studies
with a cross sectional design for several reasons. It is
conceivable that information about risk factors may be
systematically different between patients and controls.
Patient data must come from a proxy, who might recall the
medical history differently than a proxy of a control or the
control himself. In addition, prevalence is determined by both
the number of new cases over a given period of time, and by
the duration of survival once patients have the disease. In
analogy, findings of cross sectional studies can reflect the
contribution a risk factor makes to developing dementia as
well as to surviving after the dementia starts.
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Another important issue in this respect is that risk factors
may change over time.17 The impact of environmental factors,
such as smoking, diet, physical activity, and vascular disease,
may change over time both within an individual and across
birth cohorts. Risk factors such as blood pressure change with
ageing. Furthermore, the disease, once it has started, may in
turn influence the risk factor. For example, the diet of a
demented individual may change, when the person forgets to
eat his or her meals on a regular basis. Therefore, the
relationship between a risk factor and disease may differ
depending on the age the risk factor is measured relative to
the outcome.
The age related changes in risk factors make causal
inferences as to the development of dementia difficult.
Studies of blood pressure in relation to dementia form a
good example of how the relationship between risk factors
and dementia may be influenced by the moment when the
risk factor is measured.12 18 There have been conflicting
reports, with some studies suggesting that low blood pressure
is associated with dementia, whereas others report the
opposite, namely that high blood pressure is a risk factor
for dementia. Important in this respect is that blood pressure
has been shown to decrease as a consequence of dementia. It is
therefore important that this risk factor (blood pressure) is
measured before the disease process starts. However, by the
age most ageing studies begin—that is, 65 years old—
individuals have already experienced the initial neuropatho-
logic changes that eventually lead to dementia. As soon as the
disease process has started (this may be years, possibly
decades, before the dementia becomes overt), it is too late to
measure risk factors, as the disease may have started to
influence the risk factor itself.
Therefore, it seems as though risk factors should be
measured as early as possible. By now, there are several
studies with more than 20 years of follow up.19–21 These
studies, measuring midlife risk factors to predict late life
dementia, have shed some light on the perceived incon-
gruence in earlier studies. In fact, the conflicting reports with
respect to the effect of blood pressure on the development of
dementia may be entirely explained by the moment of
measuring the risk factor. Cross sectional studies suggest that
low blood pressure is associated with dementia. Studies
measuring blood pressure during midlife have consistently
shown that midlife hypertension is associated with late life
dementia.
CONCLUSIONS
c A review of the epidemiology of dementia indeed reveals
that the public health problem of dementia has reached
epidemic proportions. It affects about 6% of individuals
over 65 years of age and has a strong age dependent
prevalence. Although dementia is quite rare before 65, it
certainly does occur, and dementia should always be in
the differential diagnosis when evaluating patients with
cognitive complaints, irrespective of age. AD is the most
prevalent form of dementia, responsible for about 60–70%
of cases. VaD is the second most important cause,
accounting for 15–20%.
c In the age group 65–69 years, there are more than two
new cases per 1000 persons, every year. This number
increases almost exponentially with increasing age, until
over the age of 90 years, out of 1000 persons, 70 new cases
of dementia can be expected every year.
c Risk factors for dementia include age and the female sex,
especially at high age. Moreover, genetic factors (APOE
e4) and vascular risk factors play an important role.
c Methodological problems associated with studies of
dementia include (1) complex diagnostic procedure, (2)
insidious onset, and (3) the relationship between the
clinical syndrome and the disease as defined by the
underlying neuropathology. Finally, it is argued that
longitudinal studies are to be preferred over cross sectional
studies.
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